Comparative Pharmacology
Head-to-head clinical analysis: FABRAZYME versus KANUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABRAZYME versus KANUMA.
FABRAZYME vs KANUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fabrazyme (agalsidase beta) is a recombinant human alpha-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal alpha-galactosyl residues, thereby reducing accumulation of these substrates in tissues.
Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.
1 mg/kg intravenously every 2 weeks infused over 4-6 hours.
1 mg/kg intravenously over 4 hours once weekly.
None Documented
None Documented
Terminal elimination half-life ranges from 80 to 120 minutes (1.3-2 hours) in adults, which supports a bi-weekly intravenous dosing regimen.
Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Primarily eliminated via renal pathways; 55-65% of the administered dose is recovered in urine as unchanged drug, with less than 5% recovered in feces.
Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy